Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

1. Suppression of mitochondrial energy production by a photosynthetic bacterial cupredoxin peptide inhibits tumor growth.Signal transduction and targeted therapy · 2026
   Article
2. Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026
   Review
3. Cytostatic Bacterial Metabolites Interfere with 5-Fluorouracil, Doxorubicin and Paclitaxel Efficiency in 4T1 Breast Cancer Cells.Molecules (Basel, Switzerland) · 2024
   Article
4. MRPL48 is a novel prognostic and predictive biomarker of hepatocellular carcinoma.European journal of medical research · 2023
   Article
5. Cellular Adaptation Takes Advantage of Atavistic Regression Programs during Carcinogenesis.Cancers · 2023
   Review
6. Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma.International journal of cancer · 2023
   Article
7. Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer.Frontiers in oncology · 2023
   Article
8. PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer.Cancer research · 2022
   Article
9. The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer.Cancer metastasis reviews · 2021
   Review
10. The Epithelial and Stromal Immune Microenvironment in Gastric Cancer: A Comprehensive Analysis Reveals Prognostic Factors with Digital Cytometry.Cancers · 2021
    Article
11. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.Cancer medicine · 2021
    Article
12. The mitochondrial landscape of ovarian cancer: emerging insights.Carcinogenesis · 2021
    Review
13. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored.Cells · 2019
    Review
14. A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.Cell cycle (Georgetown, Tex.) · 2018
    Review
15. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study.Frontiers in oncology · 2018
    Article
16. Cancer Therapeutic Potential and Prognostic Value of the SLC25 Mitochondrial Carrier Family: A Review.Cancer control : journal of the Moffitt Cancer Center
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as